XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 10,099 $ 10,278
Trade accounts receivable, net of allowance for expected credit losses of $300 and $300, respectively 35,278 31,761
Inventories, net 43,821 42,215
Prepaid expenses and other current assets 5,104 5,949
Total current assets 94,302 90,203
Property, plant and equipment, net 20,670 21,117
Goodwill 37,499 37,571
Other intangible assets, net 14,867 15,107
Deferred income taxes, net 9,873 10,567
Other noncurrent assets 3,340 3,711
Total assets 180,551 178,276
Current liabilities:    
Accounts payable 13,315 11,336
Current portion of long-term debt 2,000 2,000
Accrued compensation and related benefits 2,013 3,115
Accrued expenses and other current liabilities 6,048 7,279
Total current liabilities 23,376 23,730
Long-term debt 23,140 23,624
Deferred income taxes 1,675 1,714
Other noncurrent liabilities 3,415 3,781
Total liabilities 51,606 52,849
Commitments and Contingencies  
Stockholders’ equity:    
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued 0 0
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 20,887,446 shares at March 31, 2024 and 20,783,607 shares at December 31, 2023; outstanding – 16,451,332 shares at March 31, 2024 and 16,347,493 shares at December 31, 2023 2,089 2,078
Capital in excess of par value 189,995 189,160
Accumulated deficit (37,863) (40,754)
Accumulated other comprehensive loss (3,892) (3,660)
Treasury stock - at cost; 4,436,114 shares at March 31, 2024 and 4,436,114 shares at December 31, 2023 (21,492) (21,492)
Total Ultralife Corporation equity 128,837 125,332
Non-controlling interest 108 95
Total stockholders’ equity 128,945 125,427
Total liabilities and stockholders’ equity $ 180,551 $ 178,276